What is RightBio Metrics?
RightBio Metrics operates at the intersection of medical device innovation and patient safety, focusing specifically on the critical challenge of nasogastric and orogastric tube placement. Their flagship product, the RightSpotpH Indicator, provides a sophisticated alternative to traditional, radiation-heavy verification methods like X-rays. By delivering immediate, accurate results, the company addresses a significant pain point in NICU, ICU, and emergency department settings.
The company's market position is defined by its commitment to evidence-based technology that reduces clinical risk and improves patient outcomes. By streamlining the verification process, RightBio Metrics enables healthcare professionals to perform essential procedures with greater speed and safety, effectively setting a new standard for bedside diagnostics in complex medical environments.
How much funding has RightBio Metrics raised?
RightBio Metrics has raised a total of $1.2M across 1 funding round:
Private Equity
$1.2M
Private Equity (2016): $1.2M, investors not publicly disclosed
Key Investors in RightBio Metrics
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for RightBio Metrics?
With this major strategic investment, RightBio Metrics is poised to expand its footprint across broader healthcare systems, focusing on the widespread adoption of its non-invasive verification technology. The company is expected to leverage these resources to enhance its manufacturing capabilities and deepen its penetration into critical care markets globally.
Future growth trajectories will likely involve the integration of their diagnostic indicators into standard hospital protocols, further reducing reliance on legacy imaging techniques. As the firm scales, the focus will remain on maintaining clinical excellence while navigating the complexities of enterprise-level medical device distribution and regulatory compliance.
